GlassScriptPhysician profile
Syeda Naqvi
NPI 1932625480
$1,270.75
in general payments reported to CMS, 2019-2025
11 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.18 · 2023: $156 · 2024: $274 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $467.07 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $392.22 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $102.51 | 2023-2025 | Tezspire, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $74.24 | 2023-2025 | Winrevair, Keytruda |
| Inspire Medical Systems, INC. | $50.03 | 2024-2025 | Inspire |
| United Therapeutics Corporation | $41.02 | 2025 | Tyvaso |
| Amgen INC. | $34.05 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $33.82 | 2024-2025 | Glassia |
| Ambu INC. | $27.29 | 2025 | |
| Verona Pharma, INC. | $24.71 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $23.79 | 2024 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Naqvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.